ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.650,25
0,25%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. XOMA Corporation (XOMAP)

  7. XOMA Corporation (XOMAP) News

XOMAP XOMA Corporation

25,31
0,00 (0,00%)
01 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
XOMA Corporation XOMAP NASDAQ Preference Share
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 25,31 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
25,31 25,31
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.5.202422:43EDGAR2Form 8-K - Current report
17.5.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202413:31EDGAR2Form 8-K - Current report
14.5.202413:30GLOBEXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect..
09.5.202413:45EDGAR2Form 8-K - Current report
09.5.202413:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202413:30GLOBEXOMA Reports First Quarter 2024 Financial Results and..
30.4.202413:30GLOBEXOMA Adds Economic Interests in Three First-in-Category..
25.4.202413:30GLOBEXOMA Earns $9 Million Milestone as FDA Grants Accelerated..
03.4.202415:00GLOBEXOMA Corporation Announces Closing of Tender Offer
21.3.202412:30GLOBEXOMA Declares Quarterly Preferred Stock Dividends
19.3.202421:05GLOBEXOMA Announces Calculation of Additional Price Per Share and..
11.3.202411:56EDGAR2Form S-4 - Registration of securities, business combinations
08.3.202422:34EDGAR2Form S-3 - Registration statement under Securities Act of..
08.3.202413:39EDGAR2Form 8-K - Current report
08.3.202413:30GLOBEXOMA Reports Fourth Quarter and Full Year 2023 Financial..
04.3.202423:24EDGAR2Form SC TO-T - Tender offer statement by Third Party
28.2.202413:30GLOBEXOMA to Present at Upcoming Investor Conferences in March
16.2.202415:08EDGAR2Form 8-K - Current report
16.2.202414:00GLOBEXOMA Enters into Agreement to Acquire Kinnate Biopharma for..
18.1.202414:30GLOBEXOMA Expands its Commercial Royalty and Milestone Portfolio..
16.1.202423:22EDGAR2Form SC 13D/A - General statement of acquisition of..
11.1.202422:31EDGAR2Form 8-K - Current report
11.1.202422:05GLOBEFDA Acceptance of Zevra’s Arimoclomol NDA Filing for..
10.1.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.1.202413:30GLOBEXOMA Names Owen Hughes as Chief Executive Officer and..
02.1.202413:46EDGAR2Form 8-K - Current report
02.1.202413:30GLOBEXOMA Announces Stock Repurchase Program of up to $50 Million
20.12.202313:30GLOBEXOMA Declares Quarterly Preferred Stock Dividends
19.12.202313:40EDGAR2Form 8-K - Current report
19.12.202313:30GLOBEXOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse..
07.11.202313:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202313:40EDGAR2Form 8-K - Current report
07.11.202313:30GLOBEXOMA Reports Third Quarter 2023 Financial Results and..
31.10.202312:35EDGAR2Form 8-K - Current report
31.10.202312:30GLOBEXOMA Earns $5 Million Milestone Upon FDA Acceptance of Day..
27.10.202323:06EDGAR2Form 8-K - Current report
04.10.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.10.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.9.202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.9.202313:30GLOBEXOMA Declares Quarterly Preferred Stock Dividends
11.9.202322:10EDGAR2Form 8-K - Current report
06.9.202313:30GLOBEXOMA to Present at H.C. Wainwright 25th Annual Global..
25.8.202323:09EDGAR2Form 8-K - Current report
08.8.202313:41EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
XOMAP
XOMA
TG
MWB0
MWB Fairtrade Securities...
BIT
UC4Y3P
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten